The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis

David Araújo, Michal Shteinberg, Stefano Aliberti, Pieter C. Goeminne, Adam T. Hill, Thomas C. Fardon, Dusanka Obradovic, Glenda Stone, Marion Trautmann, Angela Davis, Katerina Dimakou, Eva Polverino, Anthony De Soyza, Melissa J. McDonnell, James D. Chalmers

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients but it is not known whether it is associated with worse clinical outcomes independent of the underlying severity of disease. This study analysed data from 2596 bronchiectasis patients included from 10 different bronchiectasis clinical centres across Europe and Israel, with a 5-year follow-up period. Prevalence of P. aeruginosa chronic infection and its independent impact on exacerbations, hospitalisations, quality of life and mortality was assessed. The prevalence of P. aeruginosa chronic infection was 15.0% (n=389). P. aeruginosa was associated with a higher mortality in a univariate analysis (hazard ratio (HR) 2.02; 95% (confidence interval) CI 1.53-2.66; p<0.0001) but an independent impact on mortality was not found in a multivariate analysis (HR 0.98; 95% CI 0.70-1.36; p=0.89). P. aeruginosa was independently associated with increased mortality only in patients with frequent exacerbations (two or more per year) (HR 2.03; 95% CI 1.36-3.03; p=0.001). An independent association with worse quality of life of 7.46 points (95% CI 2.93-12.00; p=0.001) was found in a multivariable linear regression. P. aeruginosa was therefore found to be independently associated with exacerbation frequency, hospital admissions and worse quality of life. Mortality was increased in patients with P. aeruginosa particularly in the presence of frequent exacerbations.

Original languageEnglish
Article number1701953
JournalEuropean Respiratory Journal
Volume51
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Pseudomonas Infections
Bronchiectasis
Pseudomonas aeruginosa
Mortality
Quality of Life
Infection
Israel
Linear Models
Hospitalization
Multivariate Analysis
Confidence Intervals

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. / Araújo, David; Shteinberg, Michal; Aliberti, Stefano; Goeminne, Pieter C.; Hill, Adam T.; Fardon, Thomas C.; Obradovic, Dusanka; Stone, Glenda; Trautmann, Marion; Davis, Angela; Dimakou, Katerina; Polverino, Eva; De Soyza, Anthony; McDonnell, Melissa J.; Chalmers, James D.

In: European Respiratory Journal, Vol. 51, No. 2, 1701953, 01.02.2018.

Research output: Contribution to journalArticle

Araújo, D, Shteinberg, M, Aliberti, S, Goeminne, PC, Hill, AT, Fardon, TC, Obradovic, D, Stone, G, Trautmann, M, Davis, A, Dimakou, K, Polverino, E, De Soyza, A, McDonnell, MJ & Chalmers, JD 2018, 'The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis', European Respiratory Journal, vol. 51, no. 2, 1701953. https://doi.org/10.1183/13993003.01953-2017
Araújo, David ; Shteinberg, Michal ; Aliberti, Stefano ; Goeminne, Pieter C. ; Hill, Adam T. ; Fardon, Thomas C. ; Obradovic, Dusanka ; Stone, Glenda ; Trautmann, Marion ; Davis, Angela ; Dimakou, Katerina ; Polverino, Eva ; De Soyza, Anthony ; McDonnell, Melissa J. ; Chalmers, James D. / The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. In: European Respiratory Journal. 2018 ; Vol. 51, No. 2.
@article{34ac91d930a844f5bed77646d1d26886,
title = "The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis",
abstract = "Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients but it is not known whether it is associated with worse clinical outcomes independent of the underlying severity of disease. This study analysed data from 2596 bronchiectasis patients included from 10 different bronchiectasis clinical centres across Europe and Israel, with a 5-year follow-up period. Prevalence of P. aeruginosa chronic infection and its independent impact on exacerbations, hospitalisations, quality of life and mortality was assessed. The prevalence of P. aeruginosa chronic infection was 15.0{\%} (n=389). P. aeruginosa was associated with a higher mortality in a univariate analysis (hazard ratio (HR) 2.02; 95{\%} (confidence interval) CI 1.53-2.66; p<0.0001) but an independent impact on mortality was not found in a multivariate analysis (HR 0.98; 95{\%} CI 0.70-1.36; p=0.89). P. aeruginosa was independently associated with increased mortality only in patients with frequent exacerbations (two or more per year) (HR 2.03; 95{\%} CI 1.36-3.03; p=0.001). An independent association with worse quality of life of 7.46 points (95{\%} CI 2.93-12.00; p=0.001) was found in a multivariable linear regression. P. aeruginosa was therefore found to be independently associated with exacerbation frequency, hospital admissions and worse quality of life. Mortality was increased in patients with P. aeruginosa particularly in the presence of frequent exacerbations.",
author = "David Ara{\'u}jo and Michal Shteinberg and Stefano Aliberti and Goeminne, {Pieter C.} and Hill, {Adam T.} and Fardon, {Thomas C.} and Dusanka Obradovic and Glenda Stone and Marion Trautmann and Angela Davis and Katerina Dimakou and Eva Polverino and {De Soyza}, Anthony and McDonnell, {Melissa J.} and Chalmers, {James D.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1183/13993003.01953-2017",
language = "English",
volume = "51",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis

AU - Araújo, David

AU - Shteinberg, Michal

AU - Aliberti, Stefano

AU - Goeminne, Pieter C.

AU - Hill, Adam T.

AU - Fardon, Thomas C.

AU - Obradovic, Dusanka

AU - Stone, Glenda

AU - Trautmann, Marion

AU - Davis, Angela

AU - Dimakou, Katerina

AU - Polverino, Eva

AU - De Soyza, Anthony

AU - McDonnell, Melissa J.

AU - Chalmers, James D.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients but it is not known whether it is associated with worse clinical outcomes independent of the underlying severity of disease. This study analysed data from 2596 bronchiectasis patients included from 10 different bronchiectasis clinical centres across Europe and Israel, with a 5-year follow-up period. Prevalence of P. aeruginosa chronic infection and its independent impact on exacerbations, hospitalisations, quality of life and mortality was assessed. The prevalence of P. aeruginosa chronic infection was 15.0% (n=389). P. aeruginosa was associated with a higher mortality in a univariate analysis (hazard ratio (HR) 2.02; 95% (confidence interval) CI 1.53-2.66; p<0.0001) but an independent impact on mortality was not found in a multivariate analysis (HR 0.98; 95% CI 0.70-1.36; p=0.89). P. aeruginosa was independently associated with increased mortality only in patients with frequent exacerbations (two or more per year) (HR 2.03; 95% CI 1.36-3.03; p=0.001). An independent association with worse quality of life of 7.46 points (95% CI 2.93-12.00; p=0.001) was found in a multivariable linear regression. P. aeruginosa was therefore found to be independently associated with exacerbation frequency, hospital admissions and worse quality of life. Mortality was increased in patients with P. aeruginosa particularly in the presence of frequent exacerbations.

AB - Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients but it is not known whether it is associated with worse clinical outcomes independent of the underlying severity of disease. This study analysed data from 2596 bronchiectasis patients included from 10 different bronchiectasis clinical centres across Europe and Israel, with a 5-year follow-up period. Prevalence of P. aeruginosa chronic infection and its independent impact on exacerbations, hospitalisations, quality of life and mortality was assessed. The prevalence of P. aeruginosa chronic infection was 15.0% (n=389). P. aeruginosa was associated with a higher mortality in a univariate analysis (hazard ratio (HR) 2.02; 95% (confidence interval) CI 1.53-2.66; p<0.0001) but an independent impact on mortality was not found in a multivariate analysis (HR 0.98; 95% CI 0.70-1.36; p=0.89). P. aeruginosa was independently associated with increased mortality only in patients with frequent exacerbations (two or more per year) (HR 2.03; 95% CI 1.36-3.03; p=0.001). An independent association with worse quality of life of 7.46 points (95% CI 2.93-12.00; p=0.001) was found in a multivariable linear regression. P. aeruginosa was therefore found to be independently associated with exacerbation frequency, hospital admissions and worse quality of life. Mortality was increased in patients with P. aeruginosa particularly in the presence of frequent exacerbations.

UR - http://www.scopus.com/inward/record.url?scp=85041453117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041453117&partnerID=8YFLogxK

U2 - 10.1183/13993003.01953-2017

DO - 10.1183/13993003.01953-2017

M3 - Article

AN - SCOPUS:85041453117

VL - 51

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 2

M1 - 1701953

ER -